Vonoprazan Hp Dual or Triple Eradication Regimes

Efficacy and Safety of Helicobacter Pylori Eradication Dual or Triple Regimes Using Vonoprazan as the Antacid

To evaluate the efficacy and safety of dual or triple regimes for Helicobacter Pylori eradication using Vonoprazan as the antiacid agent.

Inclusion Criteria:

• Age 18 to 70 years old, both gender is eligiable;
• Patients with definite Helicobacter Pylori infection (13C/14C urea breath test, rapid urease test and fecal Helicobacter Pylori antigen test positive) ;
• Voluntary to accept Helicobacter Pylori eradication treatment;
• Females of childbearing age are required to use medically acceptable contraceptive methods during the trial and within 30 days after the trial.

Exclusion Criteria:

• Patients with contraindications to the study drug or allergic to the study drug;
• Severe organ damage and complications (such as liver cirrhosis, uremia, etc.), severe or unstable cardiopulmonary or endocrine diseases;
• Continuous use of anti-ulcer drugs, antibiotics or bismuth complexes (at least 2 weeks before the examination for Helicobacter Pylori infection);
• Pregnant and lactating women;
• Have received upper gastrointestinal surgery;
• Symptoms of dysphagia;
• Evidence of bleeding or iron deficiency anemia;
• have a history of malignant tumor;
• History of drug or alcohol abuse within the past 1 year;
• Systemic application of glucocorticoids, non-steroidal anti-inflammatory drugs, anticoagulants, and platelet aggregation inhibitors (except aspirin ≤100 mg/d);
• Persons with mental disorders;
• Received other clinical trials within the past 3 months;
• Refused to sign the informed consent.